Nautilus Biotechnology (NASDAQ:NAUT) Sets New 52-Week High – What’s Next?

Shares of Nautilus Biotechnology, Inc. (NASDAQ:NAUT) hit a new 52-week high during mid-day trading on Wednesday . The company traded as high as $4.24 and last traded at $4.0440, with a volume of 119801 shares trading hands. The stock had previously closed at $3.95.

Wall Street Analysts Forecast Growth

NAUT has been the subject of a number of recent research reports. Guggenheim lifted their target price on Nautilus Biotechnology from $2.50 to $4.00 and gave the stock a “buy” rating in a report on Friday, February 27th. Weiss Ratings restated a “sell (d-)” rating on shares of Nautilus Biotechnology in a report on Thursday, January 22nd. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $4.00.

Nautilus Biotechnology Stock Performance

The company has a market capitalization of $512.06 million, a P/E ratio of -8.61 and a beta of 1.45. The firm’s fifty day moving average is $2.39 and its 200 day moving average is $1.83.

Nautilus Biotechnology (NASDAQ:NAUT) last announced its quarterly earnings data on Thursday, February 26th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.03. On average, analysts forecast that Nautilus Biotechnology, Inc. will post -0.57 EPS for the current year.

Insider Activity

In other Nautilus Biotechnology news, CEO Sujal M. Patel acquired 25,000 shares of the company’s stock in a transaction that occurred on Wednesday, March 4th. The stock was bought at an average price of $2.61 per share, for a total transaction of $65,250.00. Following the acquisition, the chief executive officer directly owned 10,366,721 shares in the company, valued at $27,057,141.81. The trade was a 0.24% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 41.10% of the company’s stock.

Institutional Trading of Nautilus Biotechnology

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Virtu Financial LLC boosted its stake in shares of Nautilus Biotechnology by 19.6% during the fourth quarter. Virtu Financial LLC now owns 23,532 shares of the company’s stock valued at $46,000 after purchasing an additional 3,849 shares during the period. Millennium Management LLC increased its stake in Nautilus Biotechnology by 5.4% in the 4th quarter. Millennium Management LLC now owns 1,019,996 shares of the company’s stock worth $1,989,000 after buying an additional 52,448 shares during the period. Bridgeway Capital Management LLC lifted its holdings in Nautilus Biotechnology by 4.0% during the 4th quarter. Bridgeway Capital Management LLC now owns 130,000 shares of the company’s stock valued at $254,000 after buying an additional 5,000 shares in the last quarter. Captrust Financial Advisors purchased a new stake in Nautilus Biotechnology in the 4th quarter valued at about $66,000. Finally, OMERS ADMINISTRATION Corp purchased a new stake in Nautilus Biotechnology in the 4th quarter valued at about $204,000. Hedge funds and other institutional investors own 50.71% of the company’s stock.

Nautilus Biotechnology Company Profile

Nautilus Biotechnology is a life sciences company developing a next-generation proteomics platform that aims to provide high-resolution, single-molecule protein analysis. Its core technology combines proprietary microfluidics, advanced optics and custom reagents to capture and identify thousands of proteins simultaneously, offering researchers detailed insights into cellular processes and disease biology. The company’s platform is designed to improve sensitivity, reproducibility and throughput compared with traditional mass spectrometry approaches.

Founded in 2016 and headquartered in Seattle, Washington, Nautilus Biotechnology serves pharmaceutical and biotechnology companies, academic institutions and research organizations seeking to accelerate drug discovery and biomarker research.